Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem… (NCT05354557) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
United States16 participantsStarted 2022-04-26
Plain-language summary
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy.
Patients will receive iberdomide treatment beyond 12 months if they continue to derive benefit from the treatment and will continue until progression of disease or unacceptable toxicity. Follow-up will be as per standard of care for a patient on maintenance therapy, and patients will not require additional research samples.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Histologic confirmation of multiple myeloma by the enrolling institution. Cohort specific eligibility below.
✓. Age 18-75
✓. Karnofsky performance greater than or equal to 70.
✓. Recovered to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding Grade 2 neuropathy.
✓. Laboratory criteria
✓. Absolute neutrophil count (ANC) greater than or equal to 1,000/mm3 without filgrastim use in the prior 14 days.
✓. Platelet count greater than 75,000/mm3 (without platelet transfusion in the previous 7 days or thrombopoietin mimetics in the previous 28 days)
✓. Hemoglobin greater than 8 g/dL (without red blood cell transfusion in the previous 7 days)